Immuron Limited develops and commercializes orally delivered targeted polyclonal antibodies for gastrointestinal infectious diseases. The Australian biopharmaceutical company uses a hyper-immune bovine colostrum platform and markets Travelan®, an over-the-counter product for travelers’ diarrhea and digestive tract protection, in Australia, the United States and Canada.
Recurring news covers Travelan sales by region, the Australian launch of ProIBS®, research funding and collaborations for enteric pathogens, and updates on clinical programs such as IMM-124E and IMM-529. Company announcements also discuss operating results, strategic updates, distribution expansion and investor conference presentations tied to its ASX and Nasdaq listings.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.